Skip to main content
. 2008 Oct 14;99(10):1992–2003. doi: 10.1111/j.1349-7006.2008.00955.x

Figure 5.

Figure 5

Impact of rapamycin treatment on the pharmacological response to hydroxy‐tamoxifen (OH‐Tam) and to fulvestrant using 5‐bromodeoxyuridine (BrdU) cell proliferation assay. For each experimental condition, the proliferation response was assessed by BrdU labeling (treated cells versus untreated cells) as described by the supplier. (a) MCF‐7‐derived breast cancer (MVLN) and (b) resistant (R)‐MVLN cells were cultured for 4 days in steroid‐depleted, dextran‐coated and charcoal‐treated fetal calf serum (DCC medium) in the presence of 2 nM rapamycin, 20 nM rapamycin, 200 nM OH‐Tam, 200 nM OH‐Tam combined with 2 nM or 20 nM rapamycin, 100 nM fulvestrant, and 100 nM fulvestrant combined with 2 nM or 20 nM rapamycin. Results are means ± SD from three independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 according to Student's t‐test.